Skip to Content

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

Data from the COAST-study was presented as Late-breaking at ESMO 2021. In this MEDtalk Roy S. Herbst, Medical Oncology, Yale Cancer Center, USA, gives his perspective of positive results for two new combination with durvalumab.

Roy S. Herbst

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top